Solasia Pharma K.K. revised consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue of ¥1,150 million, operating loss of ¥2,150 million, loss attributable to owners of parent of ¥2,250 and basic loss per share of ¥13.41 compared to previous guidance of revenue in the range of ¥2,300 million to ¥3,800 million, operating loss in the range of ¥1,100 million to operating profit of ¥150 million, loss in the range of ¥1,200 million to profit of ¥50 million, basic loss per share in the range of ¥8.99 to basic earnings per share of ¥0.37.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27 JPY | +3.85% | +8.00% | -40.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.00% | 30.06M | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.98% | 31.28B | |
+57.86% | 25.27B | |
-16.24% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
-17.10% | 11.69B | |
+6.89% | 8.83B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022